1. Drug ads make up as much as 38% of the ads shown during commercial breaks on TV, according to iSpot.tv data, which examines ads played between the 8 p.m. and 10 p.m. prime time slots over the last year. (Stat)

2. A clinical trial found that Merck’s experimental cholesterol drug, anacetrapib, reduced the risks of heart attacks and other heart procedures but only by 9%. Due to the lackluster results, Merck executives are still considering whether to pursue FDA approval. (AP)

3. Bristol-Myers Squibb and Daiichi Sankyo will test a combination of BMS’ immuno-oncology drug, Opdivo, with Daiichi’s experimental therapy, DS-8201. The combination therapy is being tried as a treatment for patients with breast and bladder cancers. (Reuters)

4. Takeda Pharmaceuticals will pay $400 million to AstraZeneca to co-develop a treatment for Parkinson’s disease. Earlier this week AstraZeneca announced a research collaboration with Berg, an artificial intelligence firm, to identify new ways to treat Parkinson’s. (Reuters)

5. Google is again promoting Google Glass, this time as a tool for doctors to view a patient’s chart during an appointment and to connect visually impaired clients with personal assistants, among other uses. (Stat)